| Autor: |
von Gunten V; Service de Pharmacie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion. vera.vongunten@hospitalvs.ch, Sierro C; Service de Cardiologie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion., Rosiak S; Pharmacie des Hôpitaux de l'Est lémanique, Hôpital Riviera, site du Samaritain, Vevey., Weibel ML; Pharmacie des Hôpitaux de l'Est lémanique, Hôpital Riviera, site du Samaritain, Vevey., Petignat PA; Service de Médecine Interne du Centre hospitalier du Valais romand, Hôpital du Valais, Sion., Girod G; Service de Cardiologie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion., Beney J; Service de Pharmacie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion. |
| Abstrakt: |
After myocardial infarction (MI), international societies of cardiology recommend an optimal treatment associating four classes of drugs, known as BASI combination (beta-blocker, antiplatelets, statin and inhibitor of the angiotensin converting enzyme). This study shows that the implementation of locally adapted guidelines in a regional hospital (CHCVs, Sion) significantly improve the treatment quality after MI, with a 10% increase of the BASI combination at discharge. Detailed results are discussed. Finally, we provide a table summarizing the optimal treatment strategy with drug examples including doses, which will be helpful to both general practitioners and specialists. |
